Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.
The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.
International
●International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC), Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC): Primary cutaneous lymphoma – Recommendations for clinical trial design and staging, update (2022)
●Society for Immunotherapy of Cancer (SITC): Clinical practice guideline on immunotherapy for the treatment of lymphoma (2020)
●World Health Organization (WHO)-EORTC: The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas (published 2019)
●EORTC: Recommendations on blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry (2018)
●International Lymphoma Radiation Oncology Group (ILROG): Field and dose guidelines on modern radiation therapy for primary cutaneous lymphomas (2015)
●EORTC, ISCL, and USCLC: Consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders – Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma (2011)
●ISCL, USCLC, and EORTC: Consensus statement on clinical end points and response criteria in mycosis fungoides and Sézary syndrome (2011)
●EORTC and ISCL: Consensus recommendations for the management of cutaneous B-cell lymphomas (2008)
Canada
●Choosing Wisely Canada: Don't request a fine-needle aspirate (FNA) for the evaluation of suspected lymphoma (2021)
●Cancer Care Ontario (CCO): Safety considerations for the implementation of subcutaneous rituximab formulation (2018)
●CCO: Consensus pathology recommendations for complex malignant hematology (2016)
●CCO: PET imaging in lymphoma (2015)
●CCO: Rituximab in lymphoma and chronic lymphocytic leukemia – A clinical practice guideline (2015)
United States
●International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC), Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC): Primary cutaneous lymphoma – Recommendations for clinical trial design and staging, update (2022)
●USCLC: Guidelines for phototherapy of mycosis fungoides and Sézary syndrome (2016)
●USCLC: A consensus statement on large-cell transformations of mycosis fungoides – Differential diagnosis with implications for clinical management (2014)
●EORTC, ISCL, and USCLC: Consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders – Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma (2011)
●ISCL, USCLC, and EORTC: Consensus statement on clinical end points and response criteria in mycosis fungoides and Sézary syndrome (2011)
●USCLC: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy on Sézary syndrome (2011)
Europe
●International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC), Cutaneous Lymphoma Task Force of the European Organization for the Research and Treatment of Cancer (EORTC): Primary cutaneous lymphoma – Recommendations for clinical trial design and staging, update (2022)
●World Health Organization (WHO)-EORTC: The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas (published 2019)
●European Society for Medical Oncology (ESMO): Clinical practice guidelines for diagnosis, treatment and follow-up of primary cutaneous lymphomas (2018)
●ESMO: Consensus conference on malignant lymphoma – General perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma (2018)
●ESMO: Consensus conference on malignant lymphoma – Management of 'ultra-high-risk' patients (2018)
●EORTC: Consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome, update (2017)
●ESMO: Clinical practice guidelines for diagnosis, treatment and follow-up – Peripheral T-cell lymphomas (2015)
●EORTC, ISCL, and USCLC: Consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders – Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma (2011)
●ISCL, USCLC, and EORTC: Consensus statement on clinical end points and response criteria in mycosis fungoides and Sézary syndrome (2011)
●EORTC and ISCL: Consensus recommendations for the management of cutaneous B-cell lymphomas (2008)
United Kingdom
●UK consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma (2012)
●UK consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T‐cell lymphoma and chronic graft‐versus‐host disease (2008)
India
●Indian Council of Medical Research (ICMR): Consensus document for management of non Hodgkin's lymphoma (high grade) (2016)
Japan
●Japanese Skin Cancer Society: Guidelines for the management of cutaneous lymphomas, 2011 (published 2013)
